On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Can-Fite BioPharma Ltd. (NYSE: CANF) Starts Presentation at 30th Annual ROTH Conference

Can-Fite BioPharma (NYSE: CANF) is an advanced clinical stage drug development company with a platform technology that is intended to address multi-billion-dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. Piclidenoson, Can-Fite’s lead drug candidate, is currently in a phase 3 trial for rheumatoid arthritis and is expected to enter a phase 3 trial for psoriasis during 2018. The company’s liver cancer drug, Namodenoson, is in phase 2 trials for the most common form of liver cancer, hepatocellular carcinoma (“HCC”), and for the treatment of non-alcoholic steatohepatitis (“NASH”). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the FDA. The company’s third drug candidate, CF602, has demonstrated efficacy in the treatment of erectile dysfunction in preclinical studies and the company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. For more information, visit the company’s website at www.can-fite.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office


Select A Month

Contact us: 212.418.1217